Get the Stockscreener App
8.55
5.42%
-0.49
After Hours:
8.55
Upstream Bio Inc Stock (UPB) Latest News
Upstream Bio, Inc.: Promising Outlook with Strategic Positioning and Strong Trial Execution - TipRanks
William Blair Lifts Earnings Estimates for Upstream Bio - Defense World
Long UPB: Upstream Bio’s Robust Financials and Clinical Progress Signal Bullish Reversal - Invezz
Upstream Bio’s Financial Results and Strategic Progress - TipRanks
Promising Developments and Strong Financial Position Drive Buy Rating for Upstream Bio, Inc. - TipRanks
Buy Rating for Upstream Bio: Promising Clinical Progress and Unique Drug Candidate Potential - TipRanks
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times
Form 10-K Upstream Bio, Inc. For: Dec 31 - StreetInsider.com
Upstream Bio, Inc. Completes Enrollment in Phase 2 Trial of Verekitug for Chronic Rhinosinusitis and Raises $293 Million in IPO - Nasdaq
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business ... - Enid News & Eagle
Upstream Bio Secures 3-Year Runway with $470M War Chest, Advances 3 Clinical Programs - StockTitan
Rhumbline Advisers Invests $275,000 in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
AstraZeneca And GSK Put Spotlight On Nasal Polyps Space - Citeline News & Insights
Upstream Bio to Present at Upcoming March Investor Conferences - GlobeNewswire
Respiratory Disease Biotech Upstream Bio Schedules Two Major Investor Presentations in March - StockTitan
Upstream Bio (UPB) Projected to Post Earnings on Thursday - Defense World
Global Upstream Bioprocessing Equipment Market Poised for - GlobeNewswire
Upstream Bioprocessing Market Size to Reach $105.46 Bn by 2034 - BioSpace
Upstream Bio Inc (NASDAQ: UPB) – An Analysis Is What You Need - Stocks Register
‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public - BioPharma Dive
Critical Alert: Auto Industry Hit By Devastating Cyber Attacks60% Incidents Impact Millions - StockTitan
Upstream Bio (NASDAQ:UPB) Reaches New 52-Week LowHere's Why - MarketBeat
Upstream Bio (NASDAQ:UPB) Trading Down 7.3%Here's What Happened - MarketBeat
Severe Asthma FDA Approvals, Clinical Trials, Emerging Drugs, Pipeline Insights and Companies | DelveInsight - The Globe and Mail
Upstream Bio (NASDAQ:UPB) Trading 9.4% HigherStill a Buy? - MarketBeat
Waltham biotech plans to raise $150M in IPO this week - The Business Journals
Upstream Bio (UPB) to Release Quarterly Earnings on Thursday - MarketBeat
Moody Aldrich Partners LLC Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB) - MarketBeat
Chronic Rhinosinusitis with Nasal Polyps Pipeline 2024: FDA - openPR
Upstream Bio (NASDAQ:UPB) Sets New 52-Week Low – Time to Sell? - Defense World
Upstream Bio (NASDAQ:UPB) Trading Down 3.9%Time to Sell? - MarketBeat
Upstream Bio (NASDAQ:UPB) Sets New 52-Week LowTime to Sell? - MarketBeat
Modest Final Quarter Completes Shaky Biotech IPO Comeback For 2024 - News & Insights
Upstream Bio (NASDAQ:UPB) Trading Down 10.4%Time to Sell? - MarketBeat
Upstream Bio (NASDAQ:UPB) Sets New 1-Year LowWhat's Next? - MarketBeat
Sionna Therapeutics Appoints Dr. Marcella Kuhlman Ruddy and Dr. Jo Viney to its Board of Directors - citybiz
Upstream Bio (NASDAQ:UPB) Stock Price Down 7%What's Next? - MarketBeat
Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Upstream Bio (NASDAQ:UPB) Trading Up 8.5%Here's Why - MarketBeat
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
Single-use Bioprocessing Market Size to Hit USD 146.84 Bn by 2034 - Precedence Research
Upstream Bio (NASDAQ:UPB) Trading Down 3%Here's What Happened - MarketBeat
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):